In two phase @ , double-blind , @-week trials , ERASURE ( Efficacy of Response and Safety of Two Fixed Secukinumab Regimens in Psoriasis ) and FIXTURE ( Full Year Investigative Examination of Secukinumab vs. Etanercept Using Two Dosing Regimens to Determine Efficacy in Psoriasis ) , we randomly assigned @ patients ( in the ERASURE study ) and @ patients ( in the FIXTURE study ) to subcutaneous secukinumab at a dose of @ mg or @ mg ( administered once weekly for @ weeks , then every @ weeks ) , placebo , or ( in the FIXTURE study only ) etanercept at a dose of @ mg ( administered twice weekly for @ weeks , then once weekly ) .